Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and the accumulation of amyloid-β plaques and tau tangles in the brain. Current treatments are predominantly symptomatic and do not alter the underlying pathological processes, which include amyloid aggregation, tau hyperphosphorylation, synaptic dysfunction, and neuroinflammation. Nanoparticle-based drug delivery systems have emerged as a promising strategy to address these challenges by facilitating the targeted delivery of therapeutics across the blood-brain barrier, enhancing drug bioavailability, and minimizing systemic toxicity and immunogenicity through biomimetic surface modifications, optimized physicochemical properties, and targeted delivery approaches. This review examines the multifaceted role of nanoparticles in AD therapy under various pathological mechanisms. Additionally, the review explores the diagnostic potential of nanoparticles in improving the detection of AD biomarkers, offering early diagnosis and real-time monitoring of disease progression. Despite these promising developments, the clinical translation of nanoparticle-based approaches faces challenges related to biocompatibility, long-term safety, and regulatory barriers. Ongoing research and innovation are essential to optimize nanoparticle formulations, ensure their safety, and bring these advanced technologies into clinical practice. Nanotechnology represents a paradigm shift in AD management, offering the potential for more effective treatments and improved patient outcomes.
Liu et al. (Wed,) studied this question.